Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

The New England Journal of Medicine
Alex SpyropoulosMARINER Investigators

Abstract

Patients who are hospitalized for medical illness remain at risk for venous thromboembolism after discharge, but the role of extended thromboprophylaxis in the treatment of such patients is a subject of controversy. In this randomized, double-blind trial, medically ill patients who were at increased risk for venous thromboembolism on the basis of a modified International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) score of 4 or higher (scores range from 0 to 10, with higher scores indicating a higher risk of venous thromboembolism) or a score of 2 or 3 plus a plasma d-dimer level of more than twice the upper limit of the normal range (defined according to local laboratory criteria) were assigned at hospital discharge to either once-daily rivaroxaban at a dose of 10 mg (with the dose adjusted for renal insufficiency) or placebo for 45 days. The primary efficacy outcome was a composite of symptomatic venous thromboembolism or death due to venous thromboembolism. The principal safety outcome was major bleeding. Of the 12,024 patients who underwent randomization, 12,019 were included in the intention-to-treat analysis. The primary efficacy outcome occurred in 50 of 6007 patients (0.83%) who were given rivaroxaba...Continue Reading

References

Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
Nov 23, 2007·Journal of the American Society of Nephrology : JASN·Keattiyoat WattanakitAaron R Folsom
Jul 14, 2010·Annals of Internal Medicine·Russell D HullUNKNOWN EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) stud
Mar 26, 2011·Chest·Alex C SpyropoulosUNKNOWN IMPROVE Investigators
Nov 15, 2011·The New England Journal of Medicine·Samuel Z GoldhaberUNKNOWN ADOPT Trial Investigators
Dec 30, 2011·The New England Journal of Medicine·Ajay K KakkarUNKNOWN LIFENOX Investigators
Feb 8, 2013·The New England Journal of Medicine·Alexander T CohenUNKNOWN MAGELLAN Investigators
Apr 24, 2013·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Russell D HullJane Liang
Oct 18, 2013·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jens LutzKlaus Thürmel
May 28, 2016·The New England Journal of Medicine·Alexander T CohenUNKNOWN APEX Investigators

❮ Previous
Next ❯

Citations

Dec 19, 2018·International Angiology : a Journal of the International Union of Angiology·Eduardo Ramacciotti, Jawed Fareed
Jan 3, 2019·European Heart Journal·Victor AboyansUNKNOWN ESC Working Group on Aorta and Peripheral Vascular Diseases
Jan 8, 2019·Expert Opinion on Pharmacotherapy·Daniele ScarpaVittorio Pengo
Feb 28, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Tara L Knotts, Shaker A Mousa
Feb 23, 2019·Current Opinion in Nephrology and Hypertension·Jeffrey T HaMin Jun
Apr 6, 2019·Vascular Medicine·Maya Serhal, Geoffrey D Barnes
May 9, 2019·Alimentary Pharmacology & Therapeutics·Jeffrey D McCurdyMarc Carrier
Jul 14, 2019·Journal of Thrombosis and Haemostasis : JTH·Noémie KraaijpoelGrégoire Le Gal
Jul 10, 2019·Journal of Evaluation in Clinical Practice·Elaine C TungAaron M Tejani
Apr 8, 2020·Journal of Clinical Medicine·Kira MacDougall, Alex C Spyropoulos
Mar 11, 2020·The Oncologist·Rachel P RosovskyPaul D Biddinger
Mar 14, 2020·Journal of Thrombosis and Haemostasis : JTH·Thomas MoumnehPierre-Marie Roy
May 8, 2020·Circulation·Peter K HenkeUNKNOWN American Heart Association Advocacy Coordinating Committee
Jun 25, 2020·Tuberculosis and Respiratory Diseases·Hun-Gyu HwangSam Schulman
Jul 11, 2020·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Eduardo RamacciottiJawed Fareed
Aug 12, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ellen M Uppuluri, Nancy L Shapiro
Sep 5, 2020·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Samuel A Berkman, Victor F Tapson
Aug 9, 2020·Blood·Rushad PatellJeffrey I Zwicker
Dec 29, 2018·The New England Journal of Medicine·Philippe Girard, Grégoire Le Gal
Nov 21, 2019·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Alex C SpyropoulosGary E Raskob
Jul 3, 2020·Disaster Medicine and Public Health Preparedness·Alessandro CostaLuca Ragazzoni
Jun 27, 2019·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Eduardo RamacciottiJawed Fareed
Mar 19, 2019·European Journal of Preventive Cardiology·Jacob Y CaoAnthony Keech
Dec 7, 2018·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Jian ZhouWanchun Wang
Apr 17, 2019·MMW Fortschritte der Medizin·H-C Diener
Apr 11, 2020·Annals of Vascular Diseases·Nedaa Skeik, Emily Westergard
Dec 7, 2019·Hematology·Alexander T Cohen, Beverley J Hunt
Feb 29, 2020·Research and Practice in Thrombosis and Haemostasis·Tarek NafeeSamuel Z Goldhaber
Aug 25, 2020·Research and Practice in Thrombosis and Haemostasis·Rachel P RosovskyLisa Baumann Kreuziger
Feb 20, 2019·Future Cardiology·Noel C Chan, Jeffrey I Weitz
Jul 31, 2019·Jornal Vascular Brasileiro·Maria Chiara Chindamo, Marcos Arêas Marques
May 20, 2019·Journal of Thrombosis and Thrombolysis·Michela GiustozziGiancarlo Agnelli
Sep 17, 2020·TH Open : Companion Journal to Thrombosis and Haemostasis·Alex M EbiedChristina E DeRemer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Jeffrey I WeitzEINSTEIN CHOICE Investigators
The New England Journal of Medicine
Alexander T CohenAPEX Investigators
The New England Journal of Medicine
Raymond A van AdrichemPOT-KAST and POT-CAST Group
© 2022 Meta ULC. All rights reserved